Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMYP4XC)

• Drug Name: Norgestimate Drug Info
• Synonyms: Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
• Therapeutic Class: Contraceptive Agents
• Cross-matching ID:
  PubChem CID: 6540478
  ChEBI ID: CHEMBL50815
  CAS Number: CAS 20799-27-3
  TTD Drug ID: D09QZI
  INTEDE Drug ID: DR1178

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Antigen processing and presentation	2.17	0.00e+0	60/78 (76.92%)	CD8A;LGMN;CTSB;...
Estrogen signaling pathway	2.14	0.00e+0	119/137 (86.86%)	KRT19;TFF1;KRT18;...
Oocyte meiosis	1.78	4.38e-2	90/129 (69.77%)	PRKACB;CALML3;CDC20;...
Salivary secretion	1.78	3.75e-2	76/93 (81.72%)	PRKACB;PLCB1;LYZ;...
Glucagon signaling pathway	1.76	3.94e-2	89/107 (83.18%)	PRKACB;PLCB1;CALML3;...
GnRH signaling pathway	1.76	3.50e-2	80/93 (86.02%)	PRKACB;PLCB1;CALML3;...
Mucin type O-glycan biosynthesis	1.73	4.59e-2	20/36 (55.56%)	GALNT3;GALNT7;GALNT6;...
Oxidative phosphorylation	-1.73	4.49e-2	93/133 (69.92%)	COX10;COX7B;NDUFV2;...
Complement and coagulation cascades	-1.98	5.85e-3	76/85 (89.41%)	PROCR;C4BPB;C3AR1;...
Ribosome	-2.23	0.00e+0	113/158 (71.52%)	MRPS15;RPL38;RPL36A;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼